Switch theme
Sign up to access all valuation multiples
Quanterix Corp is a life sciences company that focuses on developing an ultra-sensitive digital immunoassay platform that advances precision health for life sciences research and diagnostics. The Simoa bead-based and planar array platforms designed by the company enable customers to reliably detect protein biomarkers in low concentrations in blood, serum, and other fluids that are undetectable using conventional, analog immunoassay technologies. Its products include Simoa, Assay Kits, LDTs & Assay Services, Simoa p-Tau 217, Simoa NfL LDT, Simoa p-Tau 181 LDT, Instruments, HD-X Automated Immunoassay Analyzer, SR-X Biomarker Detection System, SP-X Imaging and Analysis System, Simoa Accelerator Laboratory and others. Geographically, It operates in North America, EMEA and Asia Pacific.
2007
136
LTM Revenue $134M
LTM EBITDA -$47.8M
-$28.6M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Quanterix has a last 12-month revenue (LTM) of $134M and a last 12-month EBITDA of -$47.8M.
In the most recent fiscal year, Quanterix achieved revenue of $135M and an EBITDA of -$44.3M.
Quanterix expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Quanterix valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | $134M | XXX | $135M | XXX | XXX | XXX |
| Gross Profit | $78.1M | XXX | $81.1M | XXX | XXX | XXX |
| Gross Margin | 58% | XXX | 60% | XXX | XXX | XXX |
| EBITDA | -$47.8M | XXX | -$44.3M | XXX | XXX | XXX |
| EBITDA Margin | -36% | XXX | -33% | XXX | XXX | XXX |
| EBIT | -$60.4M | XXX | -$52.6M | XXX | XXX | XXX |
| EBIT Margin | -45% | XXX | -39% | XXX | XXX | XXX |
| Net Profit | -$47.3M | XXX | -$38.5M | XXX | XXX | XXX |
| Net Margin | -35% | XXX | -28% | XXX | XXX | XXX |
| Net Debt | XXX | XXX | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of May 30, 2025, Quanterix's stock price is $5.
Quanterix has current market cap of $202M, and EV of -$28.6M.
See Quanterix trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| -$28.6M | $202M | XXX | XXX | XXX | XXX | $-1.22 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of May 30, 2025, Quanterix has market cap of $202M and EV of -$28.6M.
Quanterix's trades at -0.2x EV/Revenue multiple, and 0.6x EV/EBITDA.
Equity research analysts estimate Quanterix's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Quanterix has a P/E ratio of -4.3x.
See valuation multiples for Quanterix and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $202M | XXX | $202M | XXX | XXX | XXX |
| EV (current) | -$28.6M | XXX | -$28.6M | XXX | XXX | XXX |
| EV/Revenue | -0.2x | XXX | -0.2x | XXX | XXX | XXX |
| EV/EBITDA | 0.6x | XXX | 0.6x | XXX | XXX | XXX |
| EV/EBIT | 0.5x | XXX | 0.5x | XXX | XXX | XXX |
| EV/Gross Profit | -0.4x | XXX | n/a | XXX | XXX | XXX |
| P/E | -4.3x | XXX | -5.2x | XXX | XXX | XXX |
| EV/FCF | n/a | XXX | 0.7x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialQuanterix's last 12 month revenue growth is 2%
Quanterix's revenue per employee in the last FY averaged $1.0M, while opex per employee averaged $1.0M for the same period.
Quanterix's rule of 40 is -31% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Quanterix's rule of X is -30% (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for Quanterix and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 2% | XXX | n/a | XXX | XXX | XXX |
| EBITDA Margin | -36% | XXX | -33% | XXX | XXX | XXX |
| EBITDA Growth | 3% | XXX | 19% | XXX | XXX | XXX |
| Rule of 40 | -31% | XXX | -31% | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | -30% | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | $1.0M | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $1.0M | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | 23% | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 99% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Philips | XXX | XXX | XXX | XXX | XXX | XXX |
| Perspective Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| SmartVest | XXX | XXX | XXX | XXX | XXX | XXX |
| InfuSystem | XXX | XXX | XXX | XXX | XXX | XXX |
| Myomo | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Quanterix acquired XXX companies to date.
Last acquisition by Quanterix was XXXXXXXX, XXXXX XXXXX XXXXXX . Quanterix acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was Quanterix founded? | Quanterix was founded in 2007. |
| Where is Quanterix headquartered? | Quanterix is headquartered in United States of America. |
| How many employees does Quanterix have? | As of today, Quanterix has 136 employees. |
| Who is the CEO of Quanterix? | Quanterix's CEO is Dr. Masoud Toloue, PhD. |
| Is Quanterix publicy listed? | Yes, Quanterix is a public company listed on NAS. |
| What is the stock symbol of Quanterix? | Quanterix trades under QTRX ticker. |
| When did Quanterix go public? | Quanterix went public in 2017. |
| Who are competitors of Quanterix? | Similar companies to Quanterix include e.g. Philips, Perspective Therapeutics, SmartVest, InfuSystem. |
| What is the current market cap of Quanterix? | Quanterix's current market cap is $202M |
| What is the current revenue of Quanterix? | Quanterix's last 12 months revenue is $134M. |
| What is the current revenue growth of Quanterix? | Quanterix revenue growth (NTM/LTM) is 2%. |
| What is the current EV/Revenue multiple of Quanterix? | Current revenue multiple of Quanterix is -0.2x. |
| Is Quanterix profitable? | Yes, Quanterix is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of Quanterix? | Quanterix's last 12 months EBITDA is -$47.8M. |
| What is Quanterix's EBITDA margin? | Quanterix's last 12 months EBITDA margin is -36%. |
| What is the current EV/EBITDA multiple of Quanterix? | Current EBITDA multiple of Quanterix is 0.6x. |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
